Compare SATL & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SATL | GERN |
|---|---|---|
| Founded | 2010 | 1990 |
| Country | United States | United States |
| Employees | 154 | 229 |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | N/A | N/A |
| Metric | SATL | GERN |
|---|---|---|
| Price | $9.80 | $1.31 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $5.50 | $2.17 |
| AVG Volume (30 Days) | 7.6M | ★ 15.7M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $88.89 | $26.91 |
| Revenue Next Year | $56.98 | $43.75 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.26 | $1.04 |
| 52 Week High | $8.90 | $2.01 |
| Indicator | SATL | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 69.17 | 32.86 |
| Support Level | $3.17 | $1.24 |
| Resistance Level | N/A | $1.49 |
| Average True Range (ATR) | 0.83 | 0.09 |
| MACD | 0.20 | -0.02 |
| Stochastic Oscillator | 99.75 | 0.00 |
Satellogic Inc is a vertically integrated Earth observation company that designs, manufactures, and operates satellite systems, delivering decision-grade insights at scale to government and commercial customers. Through an end-to-end production and operations model, it provides governments with flexible options across their journey toward sovereign Earth observation. From access to high-frequency imagery and managed space systems to full satellite ownership, to supporting autonomous data availability and long-term technological independence. It has monitoring and alert-driven workflows that help defense and intelligence agencies, civil governments, and commercial operators transition from reactive tasking to proactive decision-making, providing mission-critical data when needed.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.